Turning Point Therapeutics Future Growth
Future criteria checks 2/6
Turning Point Therapeutics is forecast to grow earnings and revenue by 24.7% and 73.9% per annum respectively while EPS is expected to grow by 27.8% per annum.
Key information
24.7%
Earnings growth rate
27.8%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 73.9% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | n/a |
Recent future growth updates
Recent updates
Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report
Jul 21We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth
Mar 23
Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth
Dec 06The Take On Turning Point Therapeutics
Dec 03Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts
Aug 15Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business
Aug 04Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer
Jun 17Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 08Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?
Feb 26Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study
Jan 29Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher
Jan 22
We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn
Jan 13Turning Point Therapeutics: An Emerging Growth Story In TKI-Resistant Cancers
Dec 28Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?
Dec 15Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer
Dec 08Turning Point Therapeutics EPS beats by $0.12, beats on revenue
Nov 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 178 | -368 | -304 | -358 | 7 |
| 12/31/2023 | 40 | -449 | -307 | -340 | 9 |
| 12/31/2022 | 11 | -392 | -271 | -293 | 7 |
| 6/30/2022 | 1 | -342 | -263 | -259 | N/A |
| 3/31/2022 | 6 | -275 | -199 | -197 | N/A |
| 12/31/2021 | 31 | -237 | -156 | -154 | N/A |
| 9/30/2021 | 31 | -205 | -136 | -133 | N/A |
| 6/30/2021 | 55 | -157 | -91 | -90 | N/A |
| 3/31/2021 | 50 | -132 | -72 | -71 | N/A |
| 12/31/2020 | 25 | -157 | -84 | -83 | N/A |
| 9/30/2020 | 25 | -131 | -65 | -63 | N/A |
| 6/30/2020 | N/A | -134 | -84 | -82 | N/A |
| 3/31/2020 | N/A | -119 | -78 | -75 | N/A |
| 12/31/2019 | N/A | -72 | -59 | -58 | N/A |
| 9/30/2019 | N/A | -60 | -53 | -52 | N/A |
| 6/30/2019 | N/A | -46 | -40 | -40 | N/A |
| 3/31/2019 | N/A | -34 | -29 | -28 | N/A |
| 12/31/2018 | N/A | -25 | -24 | -24 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TPTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TPTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TPTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TPTX's revenue (73.9% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: TPTX's revenue (73.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TPTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/17 02:57 |
| End of Day Share Price | 2022/08/16 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Turning Point Therapeutics, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Arlinda Lee | Canaccord Genuity |
| Paul Choi | Goldman Sachs |